ResearchSafe

SLU-PP-332 (SLU-PP-332 (ERR Agonist))

Category: Weight Management. Status: Research compound (preclinical).

An experimental small-molecule "exercise mimetic" that activates estrogen-related receptors (ERRs). In animal studies it increased energy expenditure and endurance and reduced fat gain without changes in food intake or activity, by pushing cells toward fat-burning metabolism.

How it works

A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise.

Key facts

  • Molecular weight: ~426 Da (small molecule, not a peptide)
  • Half-life: Not well characterized in humans
  • Bioavailability: Studied via injection in animals; oral activity under investigation
  • Storage: Store per supplier guidance; small molecules are often stable refrigerated and protected from light.

Dosing overview

  • Typical dose: No established human dose
  • Frequency: Unknown
  • Duration: Unknown
  • Route: Injection (preclinical)

Protocol notes

  • Human dosing is not established. All current data are from rodent studies.
  • Animal work used intraperitoneal injection over short study windows.
  • Treat any human use as purely experimental with unknown safety.

Reported benefits

  • Increases mitochondrial fat-burning (preclinical)
  • Improved endurance in animals
  • Reduced fat gain without appetite change (animals)
  • Acts as an "exercise mimetic"

Possible side effects

  • Human safety unknown
  • No human side-effect data
  • Potential cardiac/metabolic effects of broad ERR activation are unstudied in people

Research

  • An ERR agonist that mimics aspects of exercise (2023): In mice, SLU-PP-332 boosted oxidative metabolism, increased running capacity, and limited diet-induced fat gain.

Compare SLU-PP-332

Community discussions about SLU-PP-332

Research and educational reference only. Not medical advice.